Clarivate Plc, an information services and analytics company, provides structured information and analytics for discovery, protection, and commercialization of scientific research, innovations, and brands. It offers Web of Science products and services, such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio to organizations that plan, fund, implement, and utilize research; and Life Sciences products, including Cortellis and Newport Integrity for pharmaceutical and biotechnology companies to support research, market intelligence, and competitive monitoring in connection with the development and commercialization of new drugs. The company also provides Derwent products, which include Derwent Innovation, Techstreet, and IP Professional Services that enables its customers to evaluate the novelty of potential new products, confirm freedom to operate with respect to their product design, help them secure patent protection, assess the competitive technology landscape, and ensure that their products comply with required industry standards; CompuMark products, such as trademark screening, searching, and watching products and services for businesses and law firms; and MarkMonitor products, which helps enterprises to establish, manage, optimize, and protect their online presence. It serves government and academic institutions, life science companies, and research and development corporations in the Americas, the Middle East, Africa, Europe, and the Asia Pacific. The company was formerly known as Clarivate Analytics Plc and changed its name to Clarivate Plc in May 2020. Clarivate Plc is headquartered in London, the United Kingdom.

Clarivate Plc

Healthcare Business Insights, Part of Clarivate

CPA Global

Dialog Solutions (now Clarivate)

Markpro

Clarivate for Life Sciences & Healthcare

Clarivate for Intellectual Property

Derwent_UI/UX_early_look

Clarivate is a leading global information services provider. We connect people and organizations to intelligence they can trust to transform their perspective, their work and our world. Our subscription- and technology-based solutions are coupled with deep domain expertise and cover the areas of Academia & Government, Life Sciences & Healthcare and Intellectual Property. For more information, please visit clarivate.com.​ 

Clarivate

Ed Guntin, President and Managing Partner of Guntin & Gust, recently shared how FoundationIP has been a game-changer for his firm. Learn how this solution has forged client relationships and made his renowned Chicago-based IP law firm as trusted Clarivate partner: https://lnkd.in/gtPpskS6

#ThinkForward #Customerstories #IP

We kicked off 2024 by bringing our colleagues around the world together and inspire a Think forward mindset. We look forward to another year leading the innovation lifecycle, sharing insights from our experts and making a lasting impact on the world.

#TeamBuilding #ThinkForward

"New modalities, underpinned by scientific breakthroughs in the past decade, are achieving clinical successes and providing treatments for patients with previously unmet medical needs." - Henry Levy, President, Clarivate for Life Sciences & Healthcare

Explore the 13 new therapeutics featured on Drugs to Watch 2024 report with standout commercial and clinical potential on our blog: https://lnkd.in/gVzE4hEc

#ThinkForward #DrugstoWatch2024 #Healthcare

Explore the world of innovation and uncover awe-inspiring stories on Ideas to Innovation - Season 3. Each episode is packed with creative problem-solving strategies that lead to real-world applications on groundbreaking ideas. Hear from industry experts as they delve into their first-hand experiences, sharing their valuable insights and unique perspectives. Listen today: https://lnkd.in/gWE4duzT

Apple Podcasts: https://lnkd.in/gABCFQX
Spotify: https://lnkd.in/gukez4Ra

#ThinkForward #Innovation #Podcasts

Clarivate releases the 11th annual Drugs to Watch report identifying thirteen potential blockbuster drugs and game changers, including therapeutic advancements for breast cancer, RSV, sickle cell disease and Crohn's. 
 
"Leveraging deep industry expertise and comprehensive therapeutic area differentiated data, this year’s Drugs to Watch report identifies innovative medicines based on recent scientific breakthroughs poised to have a transformational impact on patient outcomes.” - Mike Ward, Global Head of Thought Leadership, Clarivate for Life Sciences & Healthcare
 
Read forecasting insights in the full report: https://lnkd.in/grheDDiA
  
#ThinkForward #DrugstoWatch #Healthcare

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	917.63M -	968.47M 5.54%	1.25B 29.49%	1.88B 49.67%	2.66B 41.71%	2.66B 0%	2.63B 1.17%
cost of revenue	394.21M -	396.50M 0.58%	399.12M 0.66%	626.10M 56.87%	954M 52.37%	954M 0%	1.61B 69.26%
gross profit	523.42M -	571.97M 9.28%	854.92M 49.47%	1.25B 46.30%	1.71B 36.38%	1.71B 0%	1.01B 40.55%
selling and marketing expenses				89.23M -
general and administrative expenses	360.81M -	383.09M 6.18%	553.76M 44.55%	553.76M 0%
selling general and administrative expenses	360.81M -	383.09M 6.18%	553.76M 44.55%	642.99M 16.11%	729.90M 13.52%	729.90M 0%	739.70M 1.34%
research and development expenses
other expenses		230.85M -	250.77M 8.63%	565.32M 125.44%	385.70M 31.77%	4.90B 1,170.81%	1.72B 64.96%
cost and expenses	983.72M -	1.01B 2.72%	1.20B 19.12%	1.83B 52.40%	2.07B 12.82%	2.07B 0%	2.35B 13.76%
operating expenses	589.51M -	613.94M 4.14%	804.52M 31.04%	1.21B 50.19%	1.12B 7.67%	1.12B 0%	739.70M 33.69%
interest expense			111.91M -	252.49M 125.61%	270.30M 7.05%	270.30M 0%	293.70M 8.66%
ebitda	243.32M -	259.00M 6.44%	353.55M 36.51%	580.29M 64.13%	1.30B 124.15%	1.30B 0%	982.70M 24.45%
operating income	-147.03M -	-105.71M 28.10%	50.40M 147.68%	42.48M 15.72%	590.20M 1,289.39%	-3.93B 765.13%	274.40M 106.99%
depreciation and amortization	228.46M -	237.22M 3.84%	303.15M 27.79%	537.82M 77.41%	710.50M 32.11%	710.50M 0%	708.30M 0.31%
total other income expenses net	-80.94M -	-63.74M 21.25%	-159.51M 150.25%	-300.63M 88.47%	-4.58B 1,423.24%	-4.31B 5.90%	-1.29B 70.13%
income before tax	-285.22M -	-236.51M 17.08%	-109.11M 53.87%	-258.15M 136.60%	-3.99B 1,445.26%	-3.99B 0%	-1.01B 74.62%
income tax expense	-21.29M -	5.65M 126.53%	-2.80M 149.55%	12.30M 539.37%	-28.90M 335.00%	-28.90M 0%	-101.30M 250.52%
net income	-263.93M -	-242.16M 8.25%	-106.31M 56.10%	-270.45M 154.40%	-3.96B 1,364.31%	-3.96B 0%	-911.20M 76.99%
weighted average shs out	305.25M -	305.25M 0%	273.88M 10.28%	428.60M 56.49%	630.98M 47.22%	676.10M 7.15%	671.60M 0.67%
weighted average shs out dil	305.25M -	305.25M 0%	273.88M 10.28%	428.60M 56.49%	640.77M 49.50%	678.60M 5.90%	671.60M 1.03%
eps	-0.86 -	-0.79 8.14%	-0.39 50.63%	-0.63 61.54%	-6.28 896.83%	-5.86 6.69%	-1.36 76.79%
epsdiluted	-0.86 -	-0.79 8.14%	-0.39 50.63%	-0.63 61.54%	-6.18 880.95%	-5.84 5.50%	-1.36 76.71%

NYSE:CLVT-PA

Clarivate

Last Close

6.64

30/08 20:00

Market Cap

3.97B

Beta: 1.10

Volume Today

4.06M

Avg: 31.75K

PE Ratio

−31.73

PFCF: 12.47

Preview